<a href='https://email.asam.org/t/t-i-guliult-l-n/'>Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine</a>
JAMA Network
This industry-sponsored, multicenter, open-label randomized clinical trial with 729 participants, assessed if  rapid induction (RI) for initiating extended-release buprenorphine is as safe and effective as standard induction (SI) in individuals who inject opioids or use fentanyl.  RI was well tolerated and had higher retention than SI at extended-release buprenorphine injection 2 overall and in fentanyl positive participants. Administering the second extended-release buprenorphine injection 1 week after the first was well tolerated in both the RI arm and SI arm. These findings suggest support RI for extended-release buprenorphine induction in high-risk patients and demonstrate the feasibility of administering the first 2 doses at least 1 week apart.
 
<a href='https://email.asam.org/t/t-e-guliult-l-ti/'>Read this issue of the ASAM Weekly</a>
<a href='https://email.asam.org/t/ViewEmail/t/409ED172E9728DA22540EF23F30FEDED?alternativeLink=True'>Subscribe to the ASAM Weekly</a>
<a href='https://email.asam.org/t/ViewEmail/t/7B8FCC540811FB9A2540EF23F30FEDED/C67FD2F38AC4859C/?tx=0&previewAll=1&print=1&source=PrintPreview&context=BE1559E32AC7F640D744A813E2B67A32'>Visit ASAM</a>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Lead: Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine

This Week in Addiction Medicine from ASAM

AI Chapters

AI Insights

Reviews